Zhang Yahui, Zhang Yujia, Zhong Chubin, Wang Yaqin, Wei Wenbin, Wu Guifu
Department of Cardiology, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518033, China.
School of Rehabilitation Sciences and Engineering, University of Health and Rehabilitation Sciences, 266071, Shandong, China.
Sci Rep. 2024 Dec 28;14(1):31197. doi: 10.1038/s41598-024-82485-6.
In this study, we aimed to assess the effects of enhanced external counterpulsation (EECP) and individual shear rate therapy (ISRT) on peripheral artery function in patients with lower extremity atherosclerotic disease (LEAD). We randomly assigned 45 LEAD patients to receive 35 sessions of 45 min of EECP (n = 15), ISRT (n = 15), or sham-control (n = 15). Flow-mediated dilation in the brachial artery (brachial-FMD); 6-min walk distance; blood flow in the popliteal, posterior tibial, anterior tibial, and dorsalis pedis arteries; and plasma levels were measured before and after the 7 weeks treatment. 36-item Short Form Health Survey [SF-36] was analyzed before, after 7 weeks, and 3-month follow-ups. EECP treatment significantly improved brachial-FMD and quality of life, increased walking distance, and increased blood flow and the diameters of the popliteal artery and posterior tibial artery (all P < 0.01). Conversely, ISRT markedly increased blood flow in the anterior tibial artery (P < 0.05). EECP and ISRT decreased the endothelin-1 and asymmetrical dimethylarginine levels in patients with LEAD (both P < 0.01). Additionally, sVCAM-1 was significantly reduced after EECP intervention (P = 0.004). Our findings demonstrate that EECP and ISRT have beneficial effects on walking distance, quality of life, flow-mediated dilation, endothelial-derived vasoactive agents, and inflammatory and oxidative stress in LEAD patients.Date of registration: 2021-06-21. Trial registration: ChiCTR2100048086.
在本研究中，我们旨在评估增强型体外反搏（EECP）和个体化剪切率疗法（ISRT）对下肢动脉粥样硬化疾病（LEAD）患者外周动脉功能的影响。我们将45例LEAD患者随机分为三组，分别接受35次、每次45分钟的EECP治疗（n = 15）、ISRT治疗（n = 15）或假对照治疗（n = 15）。在7周治疗前后，测量肱动脉血流介导的血管舒张功能（肱动脉-FMD）、6分钟步行距离、腘动脉、胫后动脉、胫前动脉和足背动脉的血流以及血浆水平。在治疗前、7周后和3个月随访时分析36项简明健康调查问卷[SF-36]。EECP治疗显著改善了肱动脉-FMD和生活质量，增加了步行距离，增加了腘动脉和胫后动脉的血流及直径（所有P < 0.01）。相反，ISRT显著增加了胫前动脉的血流（P < 0.05）。EECP和ISRT降低了LEAD患者的内皮素-1和不对称二甲基精氨酸水平（两者P < 0.01）。此外，EECP干预后可溶性血管细胞黏附分子-1（sVCAM-1）显著降低（P = 0.004）。我们的研究结果表明，EECP和ISRT对LEAD患者的步行距离、生活质量、血流介导的血管舒张、内皮源性血管活性物质以及炎症和氧化应激具有有益影响。注册日期：2021年6月21日。试验注册号：ChiCTR2100048086。
